News | Nuclear Imaging | December 12, 2016

Response of Colorectal Cancer to Treatment Can Be Detected as Early as One Day After a Single Administration of Drug

Molecular Targeting Technologies, Inc. (MTTI) announces that response of colorectal cancer to treatment can be detected with their innovative diagnostic agent (Tc-99m duramycin-TumorVue) as early as one day after a single administration of drug. Results from this preclinical study were published online.

“Although imaging agents such as 18F-FDG show great promise as biomarkers for early response to targeted cancer therapy, conflicting results are reported after immunotherapy. If our preclinical findings can be confirmed in patients, TumorVue has the potential to fill this gap since it does not seem to be hampered by the presence or absence of an inflammatory response,” said Professor Sigrid Stroobants of the Antwerp University Hospital (UZA).

“Detection of early treatment response will allow for improved management of cancer patients in the clinic. This study demonstrated that TumorVue™ enables readout of tumor response to targeted therapy as early as one day after start of treatment,” said Dr. Leonie Wyffels at the University of Antwerp’s Molecular Imaging Center Antwerp (UAntwerp-MICA). “The superiority of TumorVue™ over 18F-FDG for early detection of treatment response in colorectal tumors is exciting.”

Chris Pak, president and CEO of MTTI said, “We are encouraged by the results of TumorVue for detection of treatment response to targeted therapy as early as one day. Our goal is to translate these findings into patients to differentiate responders from non-responders. This innovative agent will be a powerful tool for personalized medicine where cancer patients will be spared the toxicity of ineffective therapy.”

For more information: www.uantwerp.be

Related Content

NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility
News | Radiopharmaceuticals and Tracers | July 16, 2019
NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-...
Bracco Imaging Acquires Blue Earth Diagnostics
News | Radiopharmaceuticals and Tracers | July 01, 2019
Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company...
DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
United Imaging Announces First U.S. Clinical Install of uMI 550 Digital PET/CT System
News | PET-CT | June 19, 2019
United Imaging announced the first U.S. clinical installation of the uMI 550 Digital positron emission tomography/...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...